Mesalazine (PENTASA®) in Ulcerative Colitis (MUKOSA)

Ferring

Status: Completed

Conditions: Ulcerative Colitis

Treatments: Other: Mesalazine

Study type: Observational

Funder types: Industry

Identifiers

NCT01517607

000027

Details and patient eligibility

About

This non-interventional study examines whether the patient's level of information and the consideration of the patient's preference have a positive effect on the compliance and thus also on the therapeutic success.

Enrollment: 506 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patients are treated for the first time with oral PENTASA®, e.g. following first diagnosis of ulcerative colitis for treatment of an acute episode or
• Following a therapy-free period (no previous mesalazine therapy) or due to poor response or underdosage oder lacking acceptance of the previous medication the patients are re-adjusted to oral PENTASA®,
• The patients (≥ 18 years) have been informed about the NIS and have given their written consent for participation.

Trial design

506 participants in 1 patient group

Mesalazine

Treatment:

Other: Mesalazine